Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Want to see IART full AI Analyst Report?
Total Valuation
Integra Lifesciences has a market cap or net worth of $1.25B. The enterprise value is $3.05B.
Market Cap$1.25B
Enterprise Value$3.05B
Share Statistics
Integra Lifesciences has 77,796,906 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,796,906
Owned by Insiders3.27%
Owned by Institutions27.34%
Financial Efficiency
Integra Lifesciences’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is 1.91%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.14
Return on Invested Capital (ROIC)1.91%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee371.98K
Profits Per Employee-117.49K
Employee Count4,396
Asset Turnover0.45
Inventory Turnover1.60
Valuation Ratios
The current PE Ratio of Integra Lifesciences is ―. Integra Lifesciences’s PEG ratio is -0.00025.
PE Ratio―
PS Ratio0.58
PB Ratio0.91
Price to Fair Value0.91
Price to FCF-30.70
Price to Operating Cash Flow17.28
PEG Ratio-0.00025
Income Statement
In the last 12 months, Integra Lifesciences had revenue of 1.64B and earned -516.47M in profits. Earnings per share was -6.73.
Revenue1.64B
Gross Profit845.23M
Operating Income68.32M
Pretax Income-563.50M
Net Income-516.47M
EBITDA-326.20M
Earnings Per Share (EPS)-6.73
Cash Flow
In the last 12 months, operating cash flow was 71.44M and capital expenditures -81.57M, giving a free cash flow of -10.12M billion.
Operating Cash Flow71.44M
Free Cash Flow-10.12M
Free Cash Flow per Share-0.13
Dividends & Yields
Integra Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.87
52-Week Price Change30.19%
50-Day Moving Average11.70
200-Day Moving Average12.60
Relative Strength Index (RSI)71.02
Average Volume (3m)682.69K
Important Dates
Integra Lifesciences upcoming earnings date is Jul 29, 2026, Before Open (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateJul 29, 2026
Ex-Dividend Date―
Financial Position
Integra Lifesciences as a current ratio of 2.54, with Debt / Equity ratio of 195.65%
Current Ratio2.54
Quick Ratio1.46
Debt to Market Cap1.95
Net Debt to EBITDA-5.51
Interest Coverage Ratio0.79
Taxes
In the past 12 months, Integra Lifesciences has paid -47.03M in taxes.
Income Tax-47.03M
Effective Tax Rate0.08
Enterprise Valuation
Integra Lifesciences EV to EBITDA ratio is -8.43, with an EV/FCF ratio of -88.61.
EV to Sales1.68
EV to EBITDA-8.43
EV to Free Cash Flow-88.61
EV to Operating Cash Flow54.61
Balance Sheet
Integra Lifesciences has $265.50M in cash and marketable securities with $2.04B in debt, giving a net cash position of -$1.77B billion.
Cash & Marketable Securities$265.50M
Total Debt$2.04B
Net Cash-$1.77B
Net Cash Per Share-$22.80
Tangible Book Value Per Share-$9.20
Margins
Gross margin is 53.21%, with operating margin of 4.18%, and net profit margin of -31.58%.
Gross Margin53.21%
Operating Margin4.18%
Pretax Margin-34.46%
Net Profit Margin-31.58%
EBITDA Margin-19.95%
EBIT Margin-29.19%
Analyst Forecast
The average price target for Integra Lifesciences is $18.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$18.00
Price Target Upside61.58% Upside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast1.24%
EPS Growth Forecast-1605.54%